A Phase 1 Trial of MLN8237 Plus Romidepsin for Relapsed/Refractory Aggressive B-cell and T-cell Lymphomas
Phase of Trial: Phase I
Latest Information Update: 04 Feb 2019
Price : $35 *
At a glance
- Drugs Alisertib (Primary) ; Romidepsin
- Indications B-cell lymphoma; Burkitt's lymphoma; Follicular lymphoma; Hairy cell leukaemia; Hodgkin's disease; Mantle-cell lymphoma; Peripheral T-cell lymphoma; T-cell lymphoma
- Focus Adverse reactions
- 25 Jan 2019 Status changed from active, no longer recruiting to completed.
- 18 Sep 2018 Planned primary completion date changed from 20 Mar 2018 to 1 Oct 2018.
- 18 Sep 2018 Status changed to active, no longer recruiting.